IMR Press / FBL / Volume 23 / Issue 7 / DOI: 10.2741/4647

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Towards precision medicine in ischemic stroke and transient ischemic attack

Yi Lin1,2,3,4Zixiao Li1,3,4,5Chelsea Liu6Yongjun Wang1,3,4,5,*
Show Less
1 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2 Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
3 China National Clinical Research Center for Neurological Diseases, Beijing, China
4 Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
5 Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
6 Trinity College of Arts and Sciences, Duke University, Durham, NC, USA
Front. Biosci. (Landmark Ed) 2018, 23(7), 1338–1359;
Published: 1 March 2018

Although there is no consensus on the exact definition of precision medicine, it is generally agreed upon that the term entails diagnosis and therapy tailored to the individual patient. Precision medicine has seen major advances in the past two decades, many of which are relevant to ischemic stroke or transient ischemic attack (TIA). Advances include substantial improvements in high-throughput technologies, collaborations between the fields of biology and medicine, increasingly advanced biomedical informatics, the development of multimodal brain imaging techniques, as well as the widespread usage of electronic medical records and big data. Precision medicine in ischemic stroke or TIA is still in its infancy, but there have already been changes in clinical care from a one-size-fits-all model to a more precise, individualized approach. However, further studies are urgently needed to bridge the gaps between clinical studies and precision clinical practice. We discuss here the advances and challenges for precision medicine in ischemic stroke or TIA at its current stage, focusing on genetic predispositions, pharmacogenetics, omics, brain imaging and big data.

Ischemic Stroke
Transient Ischemic Stroke
Precision Medicine
Back to top